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INTRODUCTION
The term ‘‘chordoid meningiomas’’ was first used by Kepes
et al. in 1988 to describe a meningeal tumor among young
patients. They reported 7 collected cases, and all of them exhib-
ited hypochromic/microcytic anemia, and one patient showed
dysgammaglobulinemia with bone marrow plasmacytosis
(Castleman syndrome) which disappeared after tumor removal
(1). Such tumors were composed of eosinophilic vacuolated
cells disposed in chordoma-like clusters and cords in a myxoid
matrix, and often featured a prominent lymphoplasmacellu-
lar infiltrate. The 1993 World Health Organization (WHO)
classification of Tumors of the Central Nervous System accept-
ed lymphoplasmacyte-rich meningioma and chordoid menin-
gioma as variants of meningioma (2). These tumors contain
abundant lymphoplasmacellular infiltration and were previ-
ously reported to be frequently associated with hematologi-
cal abnormalities (3-5). More recently, however, many cases
of chordoid meningioma with no hematological abnormalities
(6-8) are being reported (Table 1). The chordoid meningioma
comprises approximately 0.5% or less of all meningiomas (6).
In Korea, the first reported case was a 55-yr-old woman who
exhibited polyclonal gammopathy, which is one of the signs
of Castleman syndrome (9). We report the second case of chor-
doid meningioma, not associated with any hematologic abnor-
mality or Castleman syndrome.
CASE REPORT
A 33-yr-old man visited our hospital and his chief complaint
was visual field defect worsening over 7 yr, especially in left
infero-temporal quadrant zone. Otherwise his past medical
history was unremarkable.
Neurological examination showed no focal deficit except
left homonymous hemianopsia. In a routine laboratory test,
the hemoglobin, mean corpuscular volume and mean corpus-
cular hemoglobin were 13.7 g/dL, 90.2 fL and 30.6 pg, respec-
tively. The total protein, albumin and globulin were 7.7 g/dL,
4.5 g/dL and 3.2 g/dL, thus albumin-globulin ratio was 1.4
(reference range 1.3-2.2). There was no laboratory finding sug-
gesting hematologic abnormality or dysgammaglobulinemia.
Magnetic resonance imaging scan revealed right temporo-occip-
ital mass, which showed iso-signal intensity on T1&T2 weight-
ed image and intense uniform enhancement of solid portion
following intravenous gadolinium administration (Fig. 1).
Thus our preoperative diagnosis was meningioma.
Right temporo-occipital craniotomy was performed, and
yellowish hard mass was seen with scant vascularity. After
puncturing peripheral cystic portion, yellowish fluid was drain-
ed. There was no gross invasion to adjacent brain tissue, and the
mass was removed totally with adhering dura. 
The visual field defect was improved immediately after oper-
ation, and there is no evidence of tumor recurrence during the
7-month follow-up period.
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Chordoid Meningioma
: A Case Report
The term ‘‘chordoid meningioma’’ means meningioma, which is pathologically similar
to chordoma, and previously reported that rarely associated with microcytic anemia
and/or dysgammaglobulinemia especially in pediatric population. We present a
case of this rare variant, which comprises less than 0.5% of all meningiomas. A
33-yr-old man visited our hospital, complaining visual field defect worsening over
7 yr. Neurological examination showed left homonymous hemianopsia. The brain
magnetic resonance imaging revealed well enhancing right temporo-occipital mass
with cystic portion. Histopathologic findings of resected tumor were compatible with
chordoid meningioma which included trabeculae of eosinophilic, vacuolated
cells in a myxoid matrix with prominent lymphoplasmacellular infiltration. The neo-
plastic cells were positive for vimentin and epithelial membrane antigen and nega-
tive for glial fibrillary acidic protein and cytokeratin. This is an adult case of chordoid
meningioma without anemia or dysgammaglobulinemia.
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Pathological finding
Histologically, the tumor mainly consisted of trabeculae or
cords of eosinophilic vaculoated cells in the abundant
mucoid matrix (Fig. 2). This chordoid area comprised the
majority (about 95%) of the tumor, which intermixed with
small areas of conventional meningioma. There were promi-
nent inflammatory cell infiltrates within the mass as well as
around the tumor margin. Neither nuclear pleomorphism
including mitosis nor necrosis was found. Immunohisto-
chemically, tumor cells showed a typical membranous stain-
ing of meningioma for epithelial membrane antigen in focal
areas (Fig. 3) and diffuse cytoplasmic staining for vimentin
(Fig. 4). None of tumor cells expressed glial fibrillary acidic
protein, cytokeratin (CAM5.2), S-100 protein or p53. Ki-67
was positive in a few tumor cells. The inflammatory cells con-
sisted of mixed B- and T-lymphocytes but T-lymphocytes
predominated within the mass (Fig. 5, 6). All these findings
wereconsistent with those of chordoid meningioma (6, 10, 11).
DISCUSSION
Chordoid meningiomas show trabeculae or cords of eosino-
philic vacuolated cells in a myxoid matrix, and thus may mimic
the histological appearance of chordoma. Typical physaliphorous
tumor cells, however, are absent in chordoid meningiomas.
In addition, the presence of histologic and immunohistochem-
ical features of a classical meningioma, i.e., whorl formation
and immunohistochemical staining for vimentin and epithelial
Authors (Reference No.) Age (yr) No. of cases Systemic effect (No. of patient)
Kepes et al., 1988 (1) 8-19 (mean:14.8) 7 Anemia (7), dysgammaglobulinemia (1)
Glasier et al., 1993 15 1 Not available
Zuppan et al., 1994 10 1 No systemic effect
Kumar et al., 1996 5 1 Not available
Civit et al., 1997 21 1 Anemia
Kobata et al., 1998 (14) 15 1 Anemia
Kajiwara et al., 1999 52 1 Not available
Couce et al., 2000 (6) 12-77 (mean:47.4)* 42 No systemic effect
Yano et al., 2000 (8) 55 1 No systemic effect
Lee et al., 2001 (9) 44 1 Dysgammaglobulinemia
Mori et al., 2001 (7) 62 1 No systemic effect
*Only 2 patients were young.
Table 1. Literature review of chordoid meningioma cases
Fig. 1. Axial T1 post-contrast magnetic resonance image shows
uniformly enhanced right temporo-occipital mass with peripheral
cystic formation.
Fig. 2. The histopathology of the tumor shows microscopic finding
very similar to that of chordoma. Note cords or trabeculae of epithe-
lioid tumor cells in a myxoid stroma (H&E stain, ×200).770 J.-Y. Yeon, J.-I. Lee, J.-H. Kim, et al.
membrane antigen in the absence of prominent cytokeratin
expression, facilitates the differential diagnosis (6, 11).
The differential diagnosis of chordoid meningioma includes
chondroid chordoma, myxoid chondrosarcoma, chordoid
glioma and other variants of meningiomas (4, 6, 11-14). Chor-
domas usually locate in the midline and show strong wide-
spread staining for cytokeratin and epithelial membrane anti-
gen (4). Myxoid chondrosarcoma has not been described in the
central nervous system, and usually positive for S-100 protein
(13). Chordoid glioma is strongly glial fibrillary acidic pro-
tein-positive (12). Microcystic variant of meningioma shows
considerable overlap with some features of chordoid menin-
gioma, because it may display certain degrees of myxoid stro-
mal changes and cytoplasmic vacuolation (11, 14). However,
this variant lacks inflammatory cell infiltrates. Lymphoplasma-
cyte-rich meningiomas do not exhibit chordoid features (15).
Fig. 5. T-lymphocytes predominate within the mass (immunohis-
tochemical stain-CD3, ×200)
Fig. 6. B-lymphocytes also present within the mass (immunohisto-
chemical stain-CD20, ×200)
Fig. 4. Tumor cells are strongly reactive for vimentin (immunohisto-
chemical stain, ×400).
Fig. 3. Tumor cells show membranous expression of epithelial mem-
brane antigen (immunohistochemical stain, ×400).Chordoid Meningioma 771
In clinical aspect, the chordoid meningioma corresponds to
WHO grade II (atypical meningioma) because of its more
aggressive clinical behavior, and is recommended to be fol-
lowed up at regular intervals after surgery (10, 11).
About association of chordoid meningioma and lympho-
plasmacyte-rich meningioma with Castleman syndrome (1,
3, 5, 14), as may dysgammaglobulinemia and microcytic
hypochromic anemia especially in pediatric population, it is
postulated that the cause of Castleman syndrome is immuno-
logical host reactions to the tumor (1). Castleman’s disease
presents with localized or disseminated lymphadenopathy
(giant lymph node hyperplasia) with systemic symptoms
among some patients. The disseminated form is often accom-
panied by anemia and polyclonal hypergammaglobulinemia,
and the condition seems to be related to an overproduction
of interleukin 6, possibly produced by human herpesvirus 8
(16). Patients with localized disease can be treated effectively
with local therapy, while the initial treatment for patients with
disseminated disease is usually done with systemic glucocor-
ticoids (16). In the neurosurgical era, many cases with chordoid
meningioma revealed that such systemic manifestations dis-
appeared after the removal of the tumor (1, 3, 9, 14, 15).
It is noteworthy that chordoid and lymphoplasmacyte-rich
meningiomas were strongly associated with predominantly
B-cells and plasma cells (1, 5, 14, 15) especially in young pa-
tients and many of the cases were also associated with Castle-
man syndrome. However, Couce et al. reviewed 42 cases of
chordoid meningioma, mostly among adults (mean age of 47.4
yrs), and reported that none of them showed anemia and/or
dysgammaglobulinemia (6). Immunohistochemical staining
results of available 5 cases confirmed that the infiltrating lym-
phocytes were predominantly T-cells (6). They concluded the
chordoid meningiomas occur primarily in adults, and there
was no significant association with systemic manifestations
at least in adults. It seems that B-cells and plasma cells cause
these systemic manifestations. However, chronic inflamma-
tory infiltrates are not necessarily composed of B-cell lineage,
the chordoid meningioma may not be associated with Castle-
man syndrome. There have been a few case reports that sup-
port this (7, 8) and so does ours. Our case was a 33-yr-old man,
and he did not show any sign of Castleman syndrome. A more
comprehensive study will be required to know whether B-cells
are more prone to infiltrate the chordoid meningioma of child-
hood, and if so, why it is.
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